[{"id":"5ea8df1a-7da1-4354-867d-0af5d167ae40","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896907","created_at":"2022-04-16T16:05:58.284Z","updated_at":"2024-07-02T16:36:51.170Z","phase":"Phase 1","brief_title":"Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02896907","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" G6PD","pipe":"","alterations":" ","tags":["G6PD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 10/18/2016","start_date":" 10/18/2016","primary_txt":" Primary completion: 03/22/2018","primary_completion_date":" 03/22/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-01-18"},{"id":"34e5be18-1470-4c80-b04a-c3f608ab3951","acronym":"","url":"https://clinicaltrials.gov/study/NCT00637247","created_at":"2022-04-16T16:04:53.025Z","updated_at":"2024-07-02T16:37:01.477Z","phase":"Phase 2","brief_title":"A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer","source_id_and_acronym":"NCT00637247","lead_sponsor":"AmpliMed Corporation","biomarkers":" G6PD","pipe":"","alterations":" ","tags":["G6PD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Amplimexon (imexon)"],"overall_status":"Completed","enrollment":" Enrollment 142","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 06/01/2010","study_completion_date":" 06/01/2010","last_update_posted":"2019-03-20"}]